tbuckley/cabot-search huggingface dataset:
AB1233-HPR Extracorporeal Shock Wave Therapy in Patients with Fibromyalgia Syndrome: A Case Series Study: Table 1.
Authors: D. Tarakcı, S. Belhan, C. Algun
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Fibromyalgia (FM) is a form of nonarticular rheumatism with generalized musculoskeletal pain and tenderness at multiple charecteristic sites in absence of a clear pathophysiology (1). FM symptoms are not restricted to pain, but often include a heterogeneous group of other conditions, such as hyperalgesia, physical and mental fatigue, disrupted or non-restorative sleep, headache, irritable bowel, depression, cognitive impairment, and other functional complaints. Extracorporeal Shock Wave Therapy (ESWT) has been expanded as one of the treatment methods for the diseases of musculoskeletal system. Although there have been reports about the effectiveness of ESWT mainly on epicondylitis, plantar fasciitis, chronic pelvic pain, chronic painful heel syndrome, lymphedema, burn wound, pressure ulcer and calcific tendinitis, its effectiveness on treatment of fibromyalgia syndrome has not been reported (2). <h3>Objectives</h3> The aim of this study to investigate to effect of ESWT for Fibromyalgia patients with back pain. <h3>Methods</h3> 5 patients (4 female, 1 male) with FM were enrolled in the study. They were diagnosed with FM by a rheumatologist. Pain was evaluated with 10 cm Visual Analog Scale (VAS) and algometer was used to identify the pressure and/or force eliciting a pressure-pain threshold (kg/cm<sup>2</sup>) on the most painfull area of back as paravertebral. Beck Depression Scale (BDS) was used to evaluate depression. Also, Nottingham Health Profile (NHP) was used to evaluate emotional, social and physical health problems. ESWT was performed 2 days in a week during 3 week. ESWT was applied 2500 times to the pain trigger points of back muscles at 6 Hz using ESWT (“HC CLINIC SWT”) via an air cylinder method using the head of a 17-mm gun and low power. <h3>Results</h3> Respectively, the mean age 36.60±11.45 years and BMI 22.81±3.67 kg/cm<sup>2</sup>. Pain, depression and health profile were improved all the patients after the ESWT. It was shown outcome measures parameters of all patients before and after ESWT in Table 1. <h3>Conclusions</h3> This study was demonstrated that ESWT is effective and rapid recovery treatment modality to reduce pain, depression symptoms and health problems in patients with FM. Further research is needed to clarify outcomes among the diversity of ESWT treatment protocol. The long-term effect of ESWT remains unclear and requires further research in patients with FM. <h3>References</h3> Fassbender, K., et al. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clinical Rheumatology 1997;16(1):76-79. McClure S, Dorfmuller C. Extracorporeal shock waven therapy: theory and equipment. Clin Tech Equine Pract 2003;2:348-357. <h3>Disclosure of Interest</h3> None declared
Obstetrical Factors and the Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child
Authors: Sheldon H. Landesman, Leslie A. Kalish, David N. Burns, Howard Minkoff, Harold E. Fox, Carmen Zorrilla, Pat Garcia, Mary Glenn Fowler, Lynne Mofenson, Ruth Tuomala
Journal: New England Journal of Medicine (1996)

A substantial proportion of perinatally acquired infections with the human immunodeficiency virus type 1 (HIV-1) occur at or near delivery, which suggests that obstetrical factors may have an important influence on transmission. We evaluated the relation of such factors and other variables to the perinatal transmission of HIV-1.
Prevalence of affective disorder in a sample of young men
Authors: M A Schuckit
Journal: American Journal of Psychiatry (1982)

To evaluate the prevalence of depression among young men and the relationship between affective disturbances and drug- or alcohol-use patterns, the author mailed a questionnaire to male students and nonacademic staff, aged 21-25 years, at the University of California, San Diego. Of the 964 men responding, 173 (18%) reported a history of depression, including 69 (7%) whose depressions were serious enough to result in a major life upset. The 318 respondents with some alcohol- or drug- related life impairment (33%) were unevenly distributed among the three depressive history groups, with 44% to 48% of those with depressions also reporting substance problems while the same was true for only 30% of the depression-free men. The author advises clinicians to consider the possibility that a depressive disturbance in young populations may occur in relation to substance intake.
Review of the Nutritive Requirements of Normal Mice for Growth, Maintenance, Reproduction, and Lactation
Authors: Morris, Harold P.
Journal: JNCI Journal of the National Cancer Institute (1944)

Journal Article Review of the Nutritive Requirements of Normal Mice for Growth, Maintenance, Reproduction, and Lactation Get access Harold P. Morris Harold P. Morris senior nutrition chemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 2, October 1944, Pages 115–141, https://doi.org/10.1093/jnci/5.2.115 Published: 01 October 1944
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Authors: Brian C. Shaffer, Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, Ulrike Bacher, Betty Hamilton, Mohamed A. Kharfan-Dabaja, Ayman Saad, Corey Cutler, Erica Warlick, Ran Reshef, Baldeep Mona Wirk, Mitchell Sabloff, Omotayo Fasan, Aaron Gerds, David Marks, Richard Olsson, William Allen Wood, Luciano J. Costa, Alan M. Miller, Jorge Cortes, Andrew Daly, Tamila L. Kindwall-Keller, Rammurti Kamble, David A. Rizzieri, Jean-Yves Cahn, Robert Peter Gale, Basem William, Mark Litzow, Peter H. Wiernik, Jane Liesveld, Bipin N. Savani, Ravi Vij, Celalettin Ustun, Edward Copelan, Uday Popat, Matt Kalaycio, Richard Maziarz, Edwin Alyea, Ron Sobecks, Steven Pavletic, Martin Tallman, Wael Saber
Journal: Journal of Clinical Oncology (2016)

To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS).We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT.Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 × 10(9)/L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high (≥ 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P < .001). Increasing score was predictive of increased relapse (P < .001) and treatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismatched cohort.The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.
DDEL-07INTRAVENOUS TOCA 511 DELIVERY LEADS TO VIRAL DNA IN RESECTED HGG
Authors: Timothy Cloughesy, Michael A. Vogelbaum, Derek Ostertag, Oscar Diego, Douglas J. Jolly, Carlos Ibanez, Kadir Yagiz, Joan Robbins, Alice Chu, Andreas Niethammer, Harry Gruber, Steven N. Kalkanis
Journal: Neuro-Oncology (2015)

Recurrent high grade glioma (HGG) remains resistant to standard therapies with survival ranging from 7.2-8.1 months. A Phase 1 clinical study using an investigational retroviral replicating vector (RRV), Toca 511, in combination with investigational oral Toca FC (extended-release 5-FC), is ongoing to evaluate intravenous (IV) delivery of Toca 511 prior to tumor resection in patients with recurrent HGG. Main objectives of this study (NCT01985256) are to identify the highest tolerated dose of Toca 511 administered intravenously followed by intracranial-parenchymal injection during resection, as well as to analyze resected tumor for presence of virus and transgene. Toca 511 doses have been escalated to 4.6 x 109 TU IV/day for 3 days (1.2 x 109 TU injected into tumor bed), followed by Toca FC at 220 mg/kg/day. The highest planned dose is 9.5 x 109 TU IV/day for 5 days. As of April 8 2015, 10 subjects have been dosed without complications. Treatment is well tolerated with no related grade ≥3 AEs, no DLTs and no subjects having discontinued Toca FC for toxicity. Pharmacokinetic analysis shows consistent dose response with virus in blood 24 hours after initial IV injection enabling multi-day dosing. Tumor samples demonstrated presence of viral DNA signal in a dose dependent manner, with 7/10 tumors having detectable, and 4/10 quantifiable signal. In the top dose group, 3/5 had quantifiable signal in the tumor. Expression of yCD transgene was detectable by IHC. Approximately 4-6 weeks after resection, virus could not be detected above the lower quantification limit in blood. Urine and saliva samples were negative with a single exception (saliva). All subjects remain alive with a maximum follow-up of 14 months (median 4 months). This study confirms the successful targeting of HGG by IV delivery of Toca 511 and tolerability at tested doses. Preliminary efficacy results will be presented.
Searching for a Standard
Authors: Ezra E.W. Cohen, Everett E. Vokes
Journal: Journal of Clinical Oncology (2002)

Article Tools EDITORIAL Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.2.359 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11786560 Searching for a Standard Ezra E.W. CohenxEzra E.W. CohenSearch for articles by this author , Everett E. VokesxEverett E. VokesSearch for articles by this author Show More The University of Chicago, Chicago, IL https://doi.org/10.1200/JCO.2002.20.2.359 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
The incidence and impact of weight loss with cachexia in gastric cancer patients.
Authors: Hongli Li, Yan Li, Yuanyuan Liu, Dingzhi Huang, Ming Bai, Shaohua Ge, Ting Deng, Rubing Han, Rui Liu, Xia Wang, Yi Ba, Zhou Likun
Journal: Journal of Clinical Oncology (2015)

e20644 Background: Cachexia is prevalent in gastric malignancies and is associated with decreased survival, frequent hospitalizations and increased healthcare costs. Recently, an international consensus statement has define cancer cachexia as a multifactorial syndrome with loss of lean body mass and progressive functional impairment. Our goal was to determine the prevalence of cachexia among gastric cancer decedents using weight loss and BMI criteria in Tianjin Medical Cancer Center (Tianjin, China). Methods: We included gastric cancer patients consecutively admitted to our hospital for chemotherapy between Jan 2012 and Dec 2013 in this study. Nutritional risk was evaluated using PG-SGA and NRS 2002. Cachexia was defined >5% weight loss in the last six months or Body Mass Index (BMI) < 20 with weight loss > 2%. Baseline assessments included: hand-grip strength, quality of life (QoL), CBC and differential counts, albumin, prealbumin and C-creactive protein (CRP). Results: 165 gastric cancer patients were evaluated, 64.8% males and 35.2% females, with the mean age of 58.2 ± 12.6 years. 73.3% (n = 121) of patients met the criterion for cachexia, had significantly different albumin g/L (mean 39.7±10.5 vs 36.2C11.2, p < 0.05), prealbumin g/L (mean 0.18±0.03 vs 0.2±0.04, p < 0.05), hemoglobin g/L (mean 114.8±23.8 vs 121.2±26.1, p < 0.05), and CPR mg/L (9.6±2.3 vs 2.7±0.4, p < 0.01). Gastric cancer patients with cachexia received less chemotherapy (mean 71.3 ±19.8% vs 87.7 ± 22.3%, p < 0.01) due to haematological toxicity. Conclusions: There is a high prevalence of weight loss consistent with cachexia in gastric cancer patients with significantly decreased in albumin, prealbumin, and hemoglobin, and tolerance to chemotherapy. Cachexia therapy should initiated at diagnosis and concurrently with antineoplastic therapy.
Case 34-1966
Authors: Kurt J. Isselbacher, Hubert J. Wolfe
Journal: New England Journal of Medicine (1966)

Presentation of Case First admission. A seventy-five-year-old man was admitted to the hospital because of cirrhosis of the liver.He had been well until ten months previously, when a left inguinal herniorraphy was performed at another hospital, with the subsequent development of a hematoma in the wound, requiring evacuation. After the second operation edema of the lower extremities and genitalia and mild ascites appeared for a brief period. Two months before entry the administration of adrenocortical steroids for treatment of psoriasis was followed by the reaccumulation of ascitic fluid and peripheral edema, with a gain of 12 pounds in . . .
S5 Idiopathic Pulmonary Arterial Hypertension demonstrates a peripheral blood signature of dysregulated immunity
Authors: K Zalewska, E Groves, H Baxendale, M Southwood, J Pepke Zaba, N Morrell, M Toshner
Journal: Thorax (2015)

<h3>Introduction</h3> There is increasing evidence of an association between Idiopathic Pulmonary Arterial Hypertension (IPAH) and immune dysregulation. Amongst other evidence, autoantibodies are detected in IPAH and there is a high prevalence of autoimmune conditions associated with group 1 pulmonary arterial hypertension.<sup>1</sup> Previous work has focussed on a role for T-regulatory cells in IPAH, however, we have noted a more profound general lymphopaenia clinically, which we set out to define and investigate. <h3>Objectives</h3> To phenotype circulating leucocytes in patients with IPAH. <h3>Methods</h3> Fresh peripheral blood leucocytes from patients with IPAH were compared to age and sex-matched healthy controls. A standardised flow cytometry panel for cell surface markers of leucocyte sub-populations was adapted from the Human Immunology Project.<sup>2</sup> Additionally Ig subclasses in serum were analysed by PEG enhanced immunoturbidometric assay and nephelometry. Peripheral lung tissue from explants in patients with IPAH was compared to control tissue from lung tumour resection (distant to the tumour margin). Tissue was immunostained for complement fragments C3d and C4d by streptABC peroxidase technique and visualised with 3,39-DAB hydrochloride and imaged by light microscopy. <h3>Results</h3> Overall lymphocyte counts were significantly reduced in IPAH compared to controls (p = 0.0187). Despite this, IPAH patients demonstrated significantly increased populations of T follicular helper (Tfh) cells (p = 0.0007) and PD1<sup>+</sup>CD4<sup>+</sup> T-cells (p = 0.0028), associated with T-cell exhaustion and control of Tfh mediated humoral immunity. There was evidence of altered B-cell differentiation with increased transitional cells (p = 0.01) and decreased non-switched memory cells (p = 0.001). Ig subclasses were not statistically different between IPAH and control and complement deposition was not significantly different between disease and control in precapillary lung vessels. <h3>Conclusions</h3> There is evidence of immune dysfunction in IPAH, notably consistent with previous reports in autoimmunity. Dysregulated immunity is emerging as a potentially important factor in IPAH pathogenesis. <h3>References</h3> 1 Mouthon L, Guillevin L, Humbert M. Pulmonary arterial hypertension: an autoimmune disease? <i>Eur</i>. <i>Respir. J</i>. 2005;<b>26</b>(6):986–8 2 Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. <i>Nat. Rev. Immunol</i>. 2012;<b>12</b>(3):191–200
Retrospective analysis of multiple myeloma survival outcomes in veterans: Focus on racial differences, age, and novel therapies.
Authors: D. I. Da Graca, S. Yellapragada, Z. Yasin, C. E. Arce-Lara
Journal: Journal of Clinical Oncology (2010)

8127 Background: Historically it has been reported that survival for African American with hematologic malignancies including multiple myeloma have been poorer when compared to whites. The purpose of this review is to evaluate if these discrepancies exist in veterans with multiple myeloma. Methods: This is a retrospective analysis of a single institutional database of multiple myeloma cases from 2000 to 2008. A total of 105 patients were identified and analyzed. Of these, 103 were males and 2 were females with a median age of 67 years; 49 were African American and 56 were whites. We analyzed for differences in survival according to age, race and use of novel therapies defined as thalidomide, lenalidomide, and bortezomib. Results: Using Chi-Square analysis, we found no statistical difference in overall survival between African American and whites (900 days versus 1,192 days, p-value=0.6440). In regard to survival differences by age, patients who were diagnosed after age of 80 (n=13) had significantly worse survival outcomes (646 days versus 1,198 days, p-value=0.0108). There was an improvement in survival in patients who received novel therapies versus other myeloma treatments (1,636 days versus 585 days, p-value=0.0008 which was highly significant). Among the patients who received treatment for myeloma, 32 out of 49 whites and 25 out of 44 African American received novel therapies as defined above; there was no difference in the use of novel treatment by race using Fisher exact test (p- value=0.5228). Conclusions: Our study demonstrated that there were no differences in overall survival between African American and whites in our veteran population, hence discrepancies suggested historically were not seen in this retrospective analysis. Patients above the age of 80 years had worse outcomes. The study also showed the use of novel therapies had a significant impact on survival outcomes in this population. These results suggest that equal access to health care may be an important factor in the treatment outcomes among races, however more studies are necessary. No significant financial relationships to disclose.
OP01THE UK TOP 10 CLINICAL RESEARCH PRIORITIES IN NEURO-ONCOLOGY
Authors: R. Grant, H. Bulbeck, K. Oliver, G. Quinn, L. MacDonald, J. Day, K. Zienius, R. Morley
Journal: Neuro-Oncology (2015)

INTRODUCTION: The James Lind Alliance (JLA) supports the NIHR to develop research evidence. Chief Medical Officer Dame Sally Davies has said: “Bringing patients and clinicians together to prioritise treatment uncertainties, is at the heart of the NIHR.” A Neuro-Oncology Priority Setting Partnership was established following JLA guidelines to identify the top 10 uncertainties in diagnosis, treatment and management of primary CNS tumours. METHOD: Stakeholder representatives from a cross section of the UK brain tumour community were recruited. The scope was clinical interventions for primary brain or spinal cord tumours. The first public survey was widely publicised to patient forums, professional organisations and charities. Questions were categorised and standardised into PICO (participants, interventions, comparisons, outcomes) format. A systematic literature search was performed to ensure the questions were genuine “uncertainties”. Initial prioritisation by stakeholders was followed by a second public survey. A final workshop determined the top 10 questions using a modified Delphi and Nominal Group technique. RESULTS: Over 600 individual questions were generated from the initial survey, a patient forum and the UK Database of Uncertainties about the Effects of Treatment (DUETs). After analysis and selection, these reduced to 44 PICO questions. The second public survey reduced these further. The last 25 questions were discussed at a full-day stakeholders' workshop. The final Top 10 priorities were agreed. CONCLUSION: The brain tumour community have worked collaboratively to identify the Top 10 priorities for clinical research. These will be promoted to governmental, neuroscience and charity funders throughout 2015/16.
On-Pump versus Off-Pump CABG
Authors: John D Puskas, Michael J Mack, Craig R Smith
Journal: New England Journal of Medicine (2010)

To the Editor: In the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial, Shroyer et al. (Nov. 5 issue)1 assigned 2203 patients to receive coronary-artery bypass grafting (CABG) either with the use of cardiopulmonary bypass (on-pump CABG) or without such bypass (off-pump CABG). The trial enrolled low-risk male patients in whom avoidance of cardiopulmonary bypass was unlikely to greatly improve the expected excellent outcomes.2 In a majority of patients, CABG was performed by surgical trainees under the supervision of attending surgeons who were remarkably inexperienced in the off-pump procedure and much more experienced in the on-pump procedure. The reported 12.4% rate of intraoperative conversion from planned off-pump CABG to on-pump CABG was five times the rate reported in the national database of the Society of Thoracic Surgeons3 and is an explicit indictment of the off-pump inexperience of surgeons, trainees, and anesthesia– nursing teams participating in the ROOBY trial.4 It is illogical to conduct a randomized trial comparing patient outcomes with alternative surgical techniques among surgical operators who have grossly asymmetric experience and expertise with the two procedures that are being compared. This is the “fatal flaw” of the ROOBY trial. Off-pump CABG is a technically challenging surgical procedure that offers substantial benefit to patients at high risk for death and complications with on-pump CABG.3,5 It remains a very important tool for surgical coronary revascularization. John D. Puskas, M.D.
Case 20-2009
Authors: Mathew M. Avram, Mai Hoang
Journal: New England Journal of Medicine (2009)

A 79-year-old woman was admitted to the burn unit of this hospital because of a blistering cutaneous eruption. Five days before admission, itching on her head and back and skin lesions on her abdomen developed. Hydroxychloroquine, which she had begun taking 2 weeks earlier, was discontinued, but the rash spread to her back, arms, and legs and became painful; fever, headache, and sore throat with dysphagia developed. A diagnostic procedure was performed.
Late-Pregnancy Bleeding and Rupture of the Marginal Sinus
Authors: James Henry Ferguson
Journal: New England Journal of Medicine (1956)

THE primary purpose of this presentation is to describe further the clinical picture of rupture of the marginal sinus of the normally implanted placenta. A general plan for the management of this complication is described.It is recognized that many physicians and medical communities have been reluctant to accept this really old diagnosis; however, for lack of time, its distinctness is not defended here except for one particular. An explanation is necessary because many have raised the question whether cases of rupture of the marginal sinus are not actually abruptions of the marginal portion of the placenta. They are not, . . .